A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies

References

• Kim JY, Kim YG, Lee GM. CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol. 2012;93(3):917–30. Epub 2011/12/14. doi: 10.1007/s00253-011-3758-5. PubMed PMID: 22159888.
   PubMed Web of Science ®Google Scholar
• Li F, Vijayasankaran N, Shen A, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. MAbs. 2010;2(5):466–77. doi: 10.4161/mabs.2.5.12720. PubMed PMID: 20622510; PubMed Central PMCID: PMCPMC2958569.
   PubMed Web of Science ®Google Scholar
• Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnology & genetic engineering reviews. 2012;28:147–75. Epub 2012/05/24. PubMed PMID: 22616486.
   PubMed Web of Science ®Google Scholar
• Sola RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2010;24(1):9–21. Epub 2010/01/09. doi: 10.2165/11530550-000000000-00000. PubMed PMID: 20055529; PubMed Central PMCID: PMCPMC2805475.
   PubMed Web of Science ®Google Scholar
• Muthana SM, Campbell CT, Gildersleeve JC. Modifications of glycans: biological significance and therapeutic opportunities. ACS chemical biology. 2012;7(1):31–43. Epub 2011/12/27. doi: 10.1021/cb2004466. PubMed PMID: 22195988; PubMed Central PMCID: PMCPMC3262866.
   PubMed Web of Science ®Google Scholar
• Higel F, Seidl A, Sorgel F, Friess W. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2016;100:94–100. Epub 2016/01/18. doi: 10.1016/j.ejpb.2016.01.005. PubMed PMID: 26775146
   PubMed Web of Science ®Google Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325–34. doi: 10.1093/glycob/cwv065. PubMed PMID: 26263923; PubMed Central PMCID: PMCPMC4634315.
   PubMed Web of Science ®Google Scholar
• Huang L, Biolsi S, Bales KR, Kuchibhotla U. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Analytical biochemistry. 2006;349(2):197–207. Epub 2005/12/20. doi: 10.1016/j.ab.2005.11.012. PubMed PMID: 16360109.
   PubMed Web of Science ®Google Scholar
• Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Gawlitzek M, Lofgren J, Mehta S, Chisholm V, Modi N, et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nature biotechnology. 1999;17(11):1116–21. Epub 1999/11/05. doi: 10.1038/15104. PubMed PMID: 10545921.
   PubMed Web of Science ®Google Scholar
• Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Current opinion in immunology. 2008;20(4):471–8. Epub 2008/07/09. doi: 10.1016/j.coi.2008.06.007. PubMed PMID: 18606225.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nature reviews Drug discovery. 2009;8(3):226–34. Epub 2009/02/28. doi: 10.1038/nrd2804. PubMed PMID: 19247305.
   PubMed Web of Science ®Google Scholar
• Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(3):833–8. Epub 2015/01/07. doi: 10.1073/pnas.1418812112. PubMed PMID: 25561553; PubMed Central PMCID: PMCPMC4311811.
   PubMed Web of Science ®Google Scholar
• Hossler P, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology. 2009;19(9):936–49. Epub 2009/06/06. doi: 10.1093/glycob/cwp079. PubMed PMID: 19494347.
   PubMed Web of Science ®Google Scholar
• Abes R, Teillaud JL. Impact of Glycosylation on Effector Functions of Therapeutic IgG. Pharmaceuticals (Basel, Switzerland). 2010;3(1):146–57. Epub 2010/01/12. doi: 10.3390/ph3010146. PubMed PMID: 27713246; PubMed Central PMCID: PMCPMC3991024.
   PubMedGoogle Scholar
• Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. The Journal of biological chemistry. 2002;277(30):26733–40. Epub 2002/05/03. doi: 10.1074/jbc.M202069200. PubMed PMID: 11986321.
   PubMed Web of Science ®Google Scholar
• Santoli D, Koprowski H. Mechanisms of activation of human natural killer cells against tumor and virus-infected cells. Immunol Rev. 1979;44:125–63. doi: 10.1111/j.1600-065X.1979.tb00269.x. PubMed PMID: 153888.
   PubMed Web of Science ®Google Scholar
• Clark MR. IgG effector mechanisms. Chem Immunol. 1997;65:88–110. doi: 10.1159/000319350. PubMed PMID: 9018874.
   PubMed Web of Science ®Google Scholar
• Perussia B, Loza MJ. Assays for antibody-dependent cell-mediated cytotoxicity (ADCC) and reverse ADCC (redirected cytotoxicity) in human natural killer cells. Methods in molecular biology (Clifton, NJ). 2000;121:179–92. doi: 10.1385/1-59259-044-6:179. PubMed PMID: 10818726.
   PubMedGoogle Scholar
• Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nature reviews Immunology. 2002;2(10):735–47. Epub 2002/10/03. doi: 10.1038/nri911. PubMed PMID: 12360212.
   PubMed Web of Science ®Google Scholar
• Yamane-Ohnuki N, Satoh M. Production of therapeutic antibodies with controlled fucosylation. MAbs. 2009;1(3):230–6. Epub 2010/01/13. doi: 10.4161/mabs.1.3.8328. PubMed PMID: 20065644; PubMed Central PMCID: PMCPMC2726589.
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nature reviews Immunology. 2006;6(5):343–57. Epub 2006/04/20. doi: 10.1038/nri1837. doi: 10.1038/nri1837. PubMed PMID: 16622479.
   PubMed Web of Science ®Google Scholar
• Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng. 2001;74(4):288–94. doi: 10.1002/bit.1119. PubMed PMID: 11410853.
   PubMed Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. mAbs. 2012;4(4):475–87. Epub 2012/06/16. doi: 10.4161/mabs.20737. PubMed PMID: 22699308; PubMed Central PMCID: PMCPMC3499342.
   PubMed Web of Science ®Google Scholar
• Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol. 1995;32(17-18):1311–8. doi: 10.1016/0161-5890(95)00118-2. PubMed PMID: 8643100.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Endo T, Matsuta K, Yoshinoya S, Aikawa T, Kosuge E, Takeuchi F, Miyamoto T, Kobata A. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol. 1989;16(3):285–90. PubMed PMID: 2498512.
   PubMed Web of Science ®Google Scholar
• Ritamo I, Cloutier M, Valmu L, Neron S, Rabina J. Comparison of the glycosylation of in vitro generated polyclonal human IgG and therapeutic immunoglobulins. Mol Immunol. 2014;57(2):255–62. doi: 10.1016/j.molimm.2013.10.005. PubMed PMID: 24184880.
   PubMed Web of Science ®Google Scholar
• Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nature reviews Drug discovery. 2011;10(2):101–11. Epub 2011/02/02. doi: 10.1038/nrd3365. PubMed PMID: 21283105.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. The Journal of biological chemistry. 2003;278(5):3466–73. Epub 2002/11/13. doi: 10.1074/jbc.M210665200. PubMed PMID: 12427744.
   PubMed Web of Science ®Google Scholar
• Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004;10(18 Pt 1):6248–55. Epub 2004/09/28. doi: 10.1158/1078-0432.ccr-04-0850. PubMed PMID: 15448014.
   PubMed Web of Science ®Google Scholar
• Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer research. 2004;64(6):2127–33. Epub 2004/03/18. doi: 10.1158/0008-5472.CAN-03-2068. PubMed PMID: 15026353.
   PubMed Web of Science ®Google Scholar
• Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. Journal of immunological methods. 2005;306(1-2):151–60. Epub 2005/10/13. doi: 10.1016/j.jim.2005.08.009. PubMed PMID: 16219319.
   PubMed Web of Science ®Google Scholar
• Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11(6):2327–36. Epub 2005/03/25. doi: 10.1158/1078-0432.ccr-04-2263. PubMed PMID: 15788684.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17(1):104–18. Epub 2006/10/03. doi: 10.1093/glycob/cwl057. PubMed PMID: 17012310.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamane-Ohnuki N, Sakai N, Yamano K, Nakano R, Inoue M, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol Bioeng. 2006;94(4):680–8. Epub 2006/04/13. doi: 10.1002/bit.20880. PubMed PMID: 16609957.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007;13(6):1875–82. Epub 2007/03/17. doi: 10.1158/1078-0432.ccr-06-1335. PubMed PMID: 17363544.
   PubMed Web of Science ®Google Scholar
• Alves CS, Prajapati S. Optimizing Chinese hamster ovary cell line development via targeted control of N-glycosylation. Pharmaceutical Bioprocessing. 2015;3(7):443–61. doi:10.4155/pbp.15.25.
   Web of Science ®Google Scholar
• Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100(8):3451–61. Epub 2016/03/05. doi: 10.1007/s00253-016-7388-9. PubMed PMID: 26936774; PubMed Central PMCID: PMCPMC4803805.
   PubMed Web of Science ®Google Scholar
• Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnology and bioengineering. 2004;87(5):614–22. doi: 10.1002/bit.20151. PubMed PMID: 15352059.
   PubMed Web of Science ®Google Scholar
• Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, Wakitani M, Yamano K, Imai H, Kanda Y, Niwa R, Iida S, Uchida K, et al. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnology and bioengineering. 2004;88(7):901–8. Epub 2004/10/30. doi: 10.1002/bit.20326. PubMed PMID: 15515168.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Imai-Nishiya H, Kuni-Kamochi R, Mori K, Inoue M, Kitajima-Miyama K, Okazaki A, Iida S, Shitara K, Satoh M. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. Journal of biotechnology. 2007;130(3):300–10. Epub 2007/06/15. doi: 10.1016/j.jbiotec.2007.04.025. PubMed PMID: 17559959.
   PubMed Web of Science ®Google Scholar
• Ho DT PJ, Ho DE, Nunez B, Bang J and Ni JHT. Fucosylation of a Therapeutic Antibody Effects on Antibody-Dependent, Cell-Mediated Cytotoxicity (ADCC) Potency and Efficacy. BioProcess International. 2016;14(4):30–8.
   Google Scholar
• von Horsten HH, Ogorek C, Blanchard V, Demmler C, Giese C, Winkler K, Kaup M, Berger M, Jordan I, Sandig V. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase. Glycobiology. 2010;20(12):1607–18. Epub 2010/07/20. doi: 10.1093/glycob/cwq109. PubMed PMID: 20639190.
   PubMed Web of Science ®Google Scholar
• Puklowski A, Wenger T, Schatz S, Koenitzer J, Schaub J, Enenkel B, et al. BI-HEX(®)-GlymaxX(®)cells enable efficient production of next generation biomolecules with enhanced ADCC activity: BMC Proc. 2013;7(Suppl 6):P63. doi:10.1186/1753-6561-7-S6-P63.
   Google Scholar
• Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer immunology research. 2015;3(9):1052–62. Epub 2015/05/07. doi: 10.1158/2326-6066.cir-14-0191. PubMed PMID: 25943534.
   PubMed Web of Science ®Google Scholar
• Li X, Kimberly RP. Targeting the Fc receptor in autoimmune disease. Expert opinion on therapeutic targets. 2014;18(3):335–50. doi: 10.1517/14728222.2014.877891. PubMed PMID: 24521454; PubMed Central PMCID: PMCPMC4019044.
   PubMed Web of Science ®Google Scholar
• Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs. 2012;4(3):326–40. doi: 10.4161/mabs.19941. PubMed PMID: 22531441; PubMed Central PMCID: PMCPMC3355491.
   PubMed Web of Science ®Google Scholar
• Evans K, Albanetti T, Venkat R, Schoner R, Savery J, Miro-Quesada G, Rajan B, Groves C, et al. Assurance of monoclonality in one round of cloning through cell sorting for single cell deposition coupled with high resolution cell imaging. Biotechnology progress. 2015;31(5):1172–8. Epub 2015/07/22. doi: 10.1002/btpr.2145. PubMed PMID: 26195345; PubMed Central PMCID: PMCPMC5054913.
   PubMed Web of Science ®Google Scholar
• Niittymaki J, Mattila P, Renkonen R. Differential gene expression of GDP-L-fucose-synthesizing enzymes, GDP-fucose transporter and fucosyltransferase VII. Apmis. 2006;114(7-8):539–48. Epub 2006/08/16. doi: 10.1111/j.1600-0463.2006.apm_461.x. PubMed PMID: 16907860.
   PubMed Web of Science ®Google Scholar
• Lai T YY, Ng SK. Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production. Pharmaceuticals. 2013;6:579–603. doi: 10.3390/ph6050579.
   Google Scholar
• Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther. 2000;1(4):376–82. Epub 2000/08/10. doi: 10.1006/mthe.2000.0050. PubMed PMID: 10933956.
   PubMed Web of Science ®Google Scholar
• Diao F, White BH. A Novel Approach for Directing Transgene Expression in Drosophila: T2A-Gal4 In-Frame Fusion. Genetics. 2012;190(3):1139–44. doi: 10.1534/genetics.111.136291. PubMed PMID: 22209908; PubMed Central PMCID: PMCPMC3296248.
   PubMed Web of Science ®Google Scholar
• Hendershot LM, Ting J, Lee AS. Identity of the immunoglobulin heavy-chain-binding protein with the 78,000-dalton glucose-regulated protein and the role of posttranslational modifications in its binding function. Molecular and cellular biology. 1988;8(10):4250–6. Epub 1988/10/01. PubMed PMID: 3141786; PubMed Central PMCID: PMCPMC365497.
   PubMed Web of Science ®Google Scholar
• Degorce F. HTRF((R)): pioneering technology for high-throughput screening. Expert opinion on drug discovery. 2006;1(7):753–64. Epub 2006/12/01. doi: 10.1517/17460441.1.7.753. PubMed PMID: 23495998.
   PubMed Web of Science ®Google Scholar
• Mallick P, Schirle M, Chen SS, Flory MR, Lee H, Martin D, Ranish J, Raught B, Schmitt R, Werner T, et al. Computational prediction of proteotypic peptides for quantitative proteomics. Nat Biotechnol. 2007;25(1):125–31. doi: 10.1038/nbt1275. PubMed PMID: 17195840.
   PubMed Web of Science ®Google Scholar
• Wang H, Qian WJ, Mottaz HM, Clauss TR, Anderson DJ, Moore RJ, Camp DG 2nd, Khan AH, Sforza DM, Pallavicini M, et al. Development and evaluation of a micro- and nanoscale proteomic sample preparation method. J Proteome Res. 2005;4(6):2397–403. Epub 2005/12/13. doi: 10.1021/pr050160f. PubMed PMID: 16335993; PubMed Central PMCID: PMCPMC1781925.
   PubMed Web of Science ®Google Scholar